CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.85M | -13.07M | -15.46M | -15.61M | -14.86M |
| Total Depreciation and Amortization | 3.90K | 3.90K | 4.00K | 3.70K | 3.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 190.30K | 232.60K | 1.08M | 1.29M | 1.44M |
| Change in Net Operating Assets | 1.85M | -3.40M | -6.48M | -2.85M | -3.69M |
| Cash from Operations | -13.81M | -16.23M | -20.86M | -17.16M | -17.11M |
| Capital Expenditure | -18.20K | -4.20K | -4.20K | -4.20K | -4.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -18.20K | -4.20K | -4.20K | -4.20K | -4.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -297.60K | -298.00K | -299.10K | -300.10K | -300.90K |
| Issuance of Common Stock | 14.05M | 18.55M | 30.97M | 28.88M | 23.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 816.40K | 870.50K | 832.00K | 815.20K | -66.80K |
| Cash from Financing | 14.57M | 19.13M | 31.50M | 29.40M | 23.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 739.60K | 2.89M | 10.64M | 12.23M | 5.91M |